Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.
The company is developing dedicated product lines for next-generation sequencing that incorporate a thermal cycler capable of 35-minute PCR.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The new chip enables the firm's digital PCR system to test up to 240 samples per day, and also uses lower volumes of sample input.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
New funding will support genome-wide studies to uncover loci conferring immunity to a live-attenuated Plasmodium vaccine.
The firm also continues to use its methylation-specific PCR technology to develop assays for partners in the oncology space.
New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.